The Drugs Controller General of India (DCGI) has granted permission to Mumbai-based pharma major Cipla to import Moderna’s COVID-19 vaccine, making it the fourth vaccine in the country to be given the emergency use authorisation (EUA).
- India has made available three COVID vaccines — Covaxin, Covishield and Sputnik.
- The vaccine, mRNA-1273, manufactured by Moderna TX, Inc., is a two-dose vaccine with the shots to be given 28 days apart.
- Messenger RNA vaccines, also called mRNA vaccines, are a new vaccine technology platform.
- The mRNA vaccines teach human cells how to make a protein, or even just a piece of a protein of the virus, triggering an immune response inside human bodies.
- The benefit of mRNA vaccines, like all vaccines, is that those vaccinated gain protection without ever having to risk the serious consequences of getting sick with Covid-19.
- Vaccines and medicines, and even diagnostic tests and medical devices, require the approval of a regulatory authority before they can be administered.
- In India, the regulatory authority is the Central Drugs Standard Control Organisation (CDSCO).
- For vaccines and medicines, approval is granted after an assessment of their safety and effectiveness, based on data from trials.